We were delighted to discuss with Kim Papp (Probity Medical Research, Waterloo, ON, Canada) the results of the phase IIb study assessing the efficacy, safety and tolerability of sonelokinab (M1095), and IL-17 A/F nanobody, in patients with moderate-to-severe chronic plaques psoriasis (Clinical Trial Identifier: NCT03384745)
QuestionsÂ
- What are the major unmet needs in the treatment of chronic plaque-type psoriasis? (0:22)
- Could you tell us a little about sonelokinab and its mechanism of action? (1:29)
- What were the aims, design and inclusion criteria of the Phase IIb study? (2:58)
- What have we learned from the efficacy and safety findings of the study? (5:13)
- What will be the next steps in the clinical development of sonelokinab in this indication? (7:54)
Disclosures: Kim Papp as acted as an advisor/speaker/consultant/steering committee member/researcher for AbbVie, Akros, Allergan, Amgen, Anacor, Arcutis, Astellas, AstraZeneca, Bausch Health (Valeant), Baxalta, Baxter, Boehringer Ingelheim, Bristol-Myers Squibb, Can-Fite, Celgene, Coherus, Dermira, Dow, Forward Pharma, Galderma, Genentech, Gilead, GlaxoSmithKline, InflaRx, Janssen, Kyowa Kirin, LEO Pharma, Lilly, MedImmune, Meiji Seika Pharma, Merck, Mitsubishi Tanabe Pharma, Moberg Pharma, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Takeda, and UCB.
Support: Interview and filming supported by Touch Medical Media.
Filmed as highlights of the 29th EADV Virtual Congress 2020.
